Page 9 - Sanket Koul

Central Park to invest ₹2,000 cr in luxury residential project in Gurugram

People in the know told Business Standard that the ticket prices for the studio apartments would range between Rs 3 crore and Rs 5 crore, while that for 3 and 4 BHK apartments would be ₹11 cr, ₹15 cr

Labour codes: Real estate expects up to 10% spike in baseline labour cost

Developers expect short-term cost and timeline pressures, but say unified labour laws will bring predictability, better compliance and steadier workforce availability

ATS HomeKraft provides ₹1,250 cr exit to HDFC Capital's HCARE-2 fund

The ATS group developer cleared dues to HCARE-2 entirely through project cash flows, highlighting strong demand and healthier balance sheets in mid-income housing

MNC drugmakers push for 10-year exclusivity period for trial data

First entities' data filed for novel drugs needs protection: OPPI

Drug regulator mandates CDSCO licensing on medical device procurement

The regulator told states not to demand USFDA or EU approvals in tenders after complaints that Indian-made devices were being sidelined

SC's green clearance ruling recall could push ahead stalled projects

Move to give relief to thousands of homebuyers and developers

Mankind Pharma inks licencing pact with Actimed for cachexia treatment

Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets

NCDC refutes Lancet AMR study, says high colonisation not infection risk

The NCDC challenged a Lancet study on high MDRO colonisation in Indian ERCP patients, stating colonisation infection and India's drug-resistant infection rates are still relatively low

Serum Institute, CSIR sign pact to produce affordable gene therapy for SCD

CSIR-IGIB and Serum Institute of India have partnered to transfer indigenous CRISPR-based technology that could cut sickle cell gene therapy costs from crores to a fraction

Budget: Nathealth asks for ₹50k cr infra fund, tax SOPs for health checkups

Innovation fund for deep tech collabs, setting up of labs and 100% deduction on capex under section 35 AD of IT Act among key demands

Khan Market 24th most expensive high-street retail location globally

India's high-street retail markets recorded steady rent growth in 2025, driven by premiumisation, limited supply and strong demand in major cities, Cushman & Wakefield said

Centre launches 2nd national action plan to combat antimicrobial resistance

The new plan attempts to plug gaps identified during the implementation of the first NAP-AMR (2017-21)

NBCC sells rights for 609 Amrapali units to AU Real Estate for ₹1,069 cr

NBCC sold selling rights for 609 units in Amrapali's Aspire Leisure Valley and Centurion Park to AU Real Estate to raise funds for completing stalled housing projects

NPPA extends knee implant price ceiling by one year till November 2026

The NPPA has extended the knee implant price cap despite industry requests to remove or relax it, citing rising costs and innovation needs, as the regulator prioritises affordability for patients

India's medtech sector sets sights on tripling UK exports by 2030

A 7-member AIMED delegation explored regulatory alignment, market access and technology-sharing opportunities in the UK as India targets a sharp rise in medical device exports by 2030

Greenbay Infra launches ₹400 cr luxury project, eyes ₹1,000 cr revenue

The launch comes five months after YEIDA had warned the developer of cancelling its allotment for a 100-acre Greenbay Golf Village over failure to deposit outstanding dues at the time

India and China begin discussions for a reverse-trade model for drugs

This would unlock export potential of $6 billion for Indian pharma companies

Anant Raj to invest Rs 4,500 crore in Andhra Pradesh for data centres

Realty developer Anant Raj has signed an MoU with the Andhra Pradesh government to invest Rs 4,500 crore in a data and cloud services centre, a move expected to create nearly 16,000 jobs

Akums Q2 PAT falls 35.8% on muted CDMO biz growth, declining API prices

Despite this, the CDMO segment remained Akums' key growth driver, contributing Rs 804 crore, or 79 per cent of its total revenue

Alkem Labs Q2 profit rises 11% on strong India, international sales

India sales grew 14% Y-o-Y to ₹2,766 crore in the September quarter, while international sales rose 29.5% to ₹1,189 crore, contributing 31.7% to overall revenue